Cold therapy plus immunotherapy shows promise for lung cancer that resists first treatment

NCT ID NCT06127303

Recruiting now Disease control Sponsor: Shanghai Chest Hospital Source: ClinicalTrials.gov ↗

First seen Sep 30, 2025 · Last updated May 22, 2026 · Updated 28 times

Summary

This study is for people with advanced non-small cell lung cancer whose cancer has started to grow again after initial immunotherapy. It tests a combination of toripalimab (an immunotherapy drug) and cryoablation (a treatment that freezes and destroys tumors). The goal is to see if this combination can control the cancer and delay further progression. About 54 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Shanghai Chest Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
NOT_YET_RECRUITING

Shanghai, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Zhongshan Hospital, Fudan University
NOT_YET_RECRUITING

Shanghai, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER